CWCong Wang

Cong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cong Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4–Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy

    by Katherine K. Barnett, Abigail R. Johnson, Asha Das, Ching-Hsien J. Lee, Cong Wang, Xiaofei Wang, Elin S. Cho, Paul G. Kluetz, Lola A. Fashoyin-Aje

    On August 1, 2024, the FDA granted accelerated approval to afamitresgene autoleucel, a melanoma-associated antigen A4 (MAGE-A4)–directed genetically modified autologous T-cell immunotherapy, for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, who are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumors express MAGE-A4 as determined by FDA-approved or cleared companion diagnostic devices. Approval was based on results from the phase II, single-arm, open-label, multicenter Study ADP-0044-002. Patients received a single dose of afamitresgene autoleucel following lymphodepleting chemotherapy. Of the 44 efficacy-evaluable patients, the overall response rate was 43.2% (95% confidence interval, 28.4–59.0), with complete response in two patients (4.5%). The median duration of response was 6.0 months (95% confidence interval, 4.6–not reached) with a median follow-up of 21.9 months. Among the 44 patients, cytokine release syndrome occurred in 75% (grade ≥3, 2%), warranting a boxed warning. Grade ≥3 infections occurred in 14% of patients, and prolonged severe cytopenias also occurred. One patient developed grade 1 immune effector cell–associated neurotoxicity, and one patient developed Epstein–Barr virus–positive lymphoproliferative disease. Notably, during review of this application, the FDA identified issues with data quality and study conduct that prompted an independent re-review of imaging assessments. The results of the re-review were the basis for the FDA’s determination of substantial evidence of effectiveness. This represents the first FDA approval of a T-cell receptor gene therapy. It is also the first FDA approval specifically for synovial sarcoma, representing a new treatment modality for this rare population that lacks effective therapies.


  • FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma

    by Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million Tegenge, Adnan A. Jaigirdar, Marc R. Theoret, Tejashri Purohit-Sheth, Yvette L. Kasamon

    In June 2022, the FDA extended the indication for lisocabtagene maraleucel (liso-cel) to include adults with large B-cell lymphoma (LBCL) who have refractory disease or relapse within 12 months of first-line chemoimmunotherapy (CIT), as well as transplant-ineligible adults with refractory disease or relapse after first-line CIT. Two clinical trials evaluating a single infusion of liso-cel preceded by lymphodepleting chemotherapy supported the second-line indications. TRANSFORM is a randomized, phase 3, open-label trial comparing liso-cel with standard second-line therapy, including planned autologous hematopoietic stem cell transplantation (HSCT), in 184 transplant-eligible patients. On interim analysis, event-free survival (EFS) by independent review committee (IRC) assessment was statistically significantly improved for the liso-cel arm, with a stratified hazard ratio of 0.34 [95% confidence interval (CI), 0.22–0.51; P < 0.0001]; the estimated median EFS was 10.1 months in the liso-cel arm versus 2.3 months in the control arm. PILOT is a single-arm phase 2 trial of second-line liso-cel in patients who were transplant-ineligible due to age or comorbidities but had adequate organ function for chimeric antigen receptor (CAR) T-cell therapy. Among 61 patients who received liso-cel (median age, 74 years), the IRC-assessed complete response rate was 54% (95% CI, 41–67). Among patients achieving complete response, the estimated 1-year rate of continued response was 68% (95% CI, 45–83). Of the 268 patients combined who received liso-cel as second-line therapy for LBCL, cytokine release syndrome occurred in 45% (Grade 3, 1.3%) and CAR T-cell–associated neurologic toxicities occurred in 27% (Grade 3, 7%), warranting a continued risk evaluation and mitigation strategy.


  • Analysis of familial aggregation using recurrence risk for complex survey data

    by Cong Wang, Zhaohai Li, Barry I. Graubard

    Familial or family aggregation of a disease is important for studying possible genetic etiology of a disease. A popular and useful measure of family aggregation is recurrence risk. Household health surveys with (family) network sampling, which surveyed individuals report about disease status of themselves and specified relatives, have been shown to be useful for estimating prevalence of diseases and more recently for estimating recurrence risk of disease using nonparametric classical survey methods. Because these surveys have complex sample designs with sample weighting for differential sample selection rates, this paper extends the composite-likelihood estimation and hypothesis of parameters of the quadratic exponential model (QEM) for simple random samples to data from these complex sample designs. In addition, the QEM is extended to simultaneously estimate and test parameters and recurrence risk for multiple family relationships, for comparing recurrence risk across family-level covariates (e.g. race) and utilizing propensity score weighting to adjust for confounding by individual-level covariates (e.g. age). Simulations are used to study the finite sample properties of the parameter estimation, variance estimation and level and power of hypothesis testing based on derived Wald and Quasi-Score tests for these extended QEMs. Finally, our methods are illustrated using the 1976 National Health Interview Survey diabetes data set.